Jump Therapeutics

At 40nM treatment concentrations, our SSO achieves significant reductions in viability compared with scrambled negative control oligonucleotide treatment in H1299 cells expressing the TE-derived LIN28B oncogene target. 40nM transfection followed by qPCR showed a ~40% reduction in LIN28B mRNA and western blot revealed a perceptible reduction in LIN28B protein expression at 40nM and 60nM compared to equal concentrations of the scrambled negative control antisense oligonucleotide.